Year Two After the Sale: When the Honeymoon Ends and the Reckoning Begins

The Transition

Year one inside a PE-backed platform is managed. The integration team is attentive. The platform leadership is accessible. The physicians are still being treated as partners whose goodwill matters to the investment thesis. There is a shared interest in making the first year look successful.

Year two is different. The integration is largely complete. The platform has moved on to its next acquisition. The physicians are now expected to perform within the system that was built for them, and the system was built to optimize for the platform's financial objectives, which are related to but not identical to the physicians' objectives.

This is not a betrayal. It is the natural evolution of a private equity investment. The firm raised capital with a mandate to generate returns. The platform was built to aggregate practices, improve their financial performance, and sell the portfolio at a higher multiple. The physicians knew this when they signed. But knowing it abstractly and experiencing it concretely are different things.

The Productivity Conversation

By year two, most PE-backed platforms have had the productivity conversation with at least some of their physician groups. The conversation goes something like this: the platform's financial model requires a certain level of productivity across the portfolio to support the valuation at the next sale. The practice is below that level. The physicians need to see more patients.

This conversation is often framed as a clinical autonomy issue, and the physicians push back on that framing. They are not being told how to practice medicine. They are being told how many patients to see. The platform's position is that this is an operational and financial matter, not a clinical one.

The physicians' position is that the number of patients they can see while maintaining the quality of care they were trained to deliver is a clinical judgment, not a financial one. Both positions are defensible. Neither resolves the tension.

The outcome of this conversation varies. In some practices, the physicians accommodate the productivity targets and accept the tradeoff. In others, they push back and the platform accommodates them, at least temporarily. In others, the tension becomes a slow-burning conflict that affects morale, retention, and eventually the quality of the practice.

The Staffing Reality

Year two is also when the staffing consequences of the sale become clear. The platform's HR function manages hiring, compensation, and benefits across the portfolio. The economics are presented as favorable because of scale. In practice, the compensation structures that the platform uses to attract and retain staff are designed for the median practice in the portfolio, not for the specific market, culture, and patient population of any individual group.

Practices that were able to attract and retain excellent staff through a combination of competitive pay, a strong culture, and the intangible appeal of working in a physician-owned environment find that the platform's standardized HR approach does not replicate those advantages. Turnover increases. The physicians notice. The platform's response is usually to point to the compensation data showing that the practice is paying at or above market.

What the compensation data does not capture is the cultural dimension of what was lost. A physician-owned practice where the physicians are present, engaged, and accountable to the team is a different working environment than a unit in a portfolio managed from a corporate office in another city. Staff feel the difference even when they cannot articulate it precisely.

The Rollover Equity Calculation

By year two, the physicians who paid attention to the deal structure are doing the math on their rollover equity. The calculation is more complicated than it appeared at close.

The rollover equity represents a percentage of the platform, not of the individual practice. The platform's value at the next sale depends on the EBITDA of all the practices in the portfolio, the multiple that the next buyer is willing to pay, and the debt that was used to finance the acquisitions. The physicians have limited visibility into any of these variables and no control over them.

What they do have visibility into is the performance of their own practice. And by year two, many of them have noticed that the platform's cost structure, the management fees, the vendor contracts, the corporate overhead allocated to the practice, is higher than they anticipated. The EBITDA that will drive their rollover equity value is being calculated after those costs are deducted. The number is smaller than the pitch implied.

This is not fraud. The costs were disclosed, in the financial schedules attached to the letter of intent, in language that required a sophisticated financial advisor to interpret. Most physicians did not have that advisor, or did not have one who was sufficiently adversarial on their behalf.

What Physicians Do in Year Two

The responses to year two vary by physician and by practice.

Some physicians adapt. They accept the new operating environment, adjust their expectations, and focus on the aspects of practice they can still control. They are not happy about what they gave up, but they have made peace with the decision and are focused on the future.

Some physicians begin the quiet process of positioning themselves for the next transaction. They are performing well, maintaining their patient relationships, and waiting for the platform to sell so they can evaluate whether the rollover equity was worth it. They are not committed to staying in the platform beyond the next liquidity event.

Some physicians begin to explore their options. They consult employment attorneys about their non-compete agreements. They have conversations with other groups in the market. They think about what it would take to start over. Most of them conclude that the non-compete and the financial structure make exit prohibitively difficult in the near term. They stay, but they stay differently than they started.

A small number leave. They accept the financial cost of breaking the non-compete, or they wait for it to expire, or they find a geographic or specialty carve-out that allows them to practice outside its scope. These physicians are the ones who are most willing to talk about what year two was actually like, because they have already paid the price of the decision and have nothing left to protect.

What This Means

The story of year two is not a story about bad actors. The PE firms are doing what PE firms do. The platform management teams are executing the strategy they were hired to execute. The physicians made a decision with incomplete information about what the experience would actually feel like, and they are living with the consequences.

The lesson for practices that have not sold is not that PE is always wrong. It is that the decision to sell should be made with a clear-eyed understanding of what year two looks like, not just what the letter of intent says. The physicians who are most at peace with their decision are the ones who went in knowing what they were trading and decided the trade was worth it. The ones who are least at peace are the ones who believed the pitch more than the structure.

The practices that are most resistant to the PE pitch are not the ones that are ideologically opposed to private equity. They are the ones that have built the operational infrastructure to compete without it. They are profitable, well-run, and in control of their own trajectory. The pitch does not land the same way when the practice does not need what the pitch is offering.

That is the real argument for operational discipline in an independent practice. Not that it is morally superior to selling. But that it keeps the decision yours to make.